Tyrosine kinase inhibitors (TKIs) are molecular targeting agents used to treat various types of cancer. During the treatment with TKIs, acid-reducing agents (ARAs) are prescribed to prevent gastric mucosal damage. However, this co-administration causes increased gastric pH resulting in reduced exposure to TKIs. Thus, avoidance of this interaction through formulation intervention is necessary to have better efficacy. The objective of the present work is to demonstrate the utility of physiologically based biopharmaceutics (PBBM) in predicting and circumventing the interactions of TKIs with ARAs. PBBM was developed for dasatinib, bosutinib, and gefitinib using physicochemical, pharmacokinetic, and physiological inputs. The models were validated against oral and intravenous clinical data. The model successfully predicted ARA interactions (stomach pH is changed to 5 to mimic ARA administration), that are in line with literature-reported data. Solubility generated in the presence of citric acid demonstrated enhanced solubility in the pH range of 4.5–6.8 for all drugs. Integration of enhanced solubility in PBBM demonstrated a nullified ARA effect for all drugs. This result indicated the possibility of dose reduction and reduced intestinal precipitation due to the acidifying effect of citric acid. Overall, PBBM successfully demonstrated potential in predicting and circumventing the ARA effect to enhance the efficacy of TKIs.
Kollipara S, Sivadasu P, Rashmi SR, Ravi PR, Guntupalli C. Role of physiologically based biopharmaceutics modeling in predicting and circumventing the drug-drug interactions of tyrosine kinase inhibitors with acid-reducing agents. J Appl Pharm Sci. 2025. Online First. http://doi.org/10.7324/JAPS.2025.234298
1. Li J, Kuang X. Global cancer statistics of young adults and its changes in the past decade: incidence and mortality from GLOBOCAN 2022. Public Health. 2024;237:336–43. doi: https://doi.org/10.1016/j.puhe.2024.10.033
2. Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18:1579–89. doi: https://doi.org/10.1016/S1470-2045(17)30677-0
3. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. doi: https://doi.org/10.3322/caac.21834
4. Weeden CE, Hill W, Lim EL, Grönroos E, Swanton C. Impact of risk factors on early cancer evolution. Cell. 2023;186:1541–63. Available from: http://www.cell.com/article/S009286742300274X/fulltext
5. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1192–308. doi: https://doi.org/10.1093/jnci/66.6.1192
6. Li Q, Geng S, Luo H, Wang W, Mo Y-Q, Luo Q, et al. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Signal Transduct Target Ther. 2024;9(1):1–48. Available from: https://www.nature.com/articles/s41392-024-01953-7
7. Kinnel B, Singh SK, Oprea-Ilies G, Singh R. Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers. 2023;15:1320. Available from: https://www.mdpi.com/2072-6694/15/4/1320/htm
8. Li S, de Camargo Correia GS, Wang J, Manochakian R, Zhao Y, Lou Y. Emerging targeted therapies in advanced non-small-cell lung cancer. Cancers. 2023;15:2899. Available from: https://www.mdpi.com/2072-6694/15/11/2899/htm
9. Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). J Hematol Oncol. 2020;13:1–23. doi: https://doi.org/10.1186/s13045-020-00977-0
10. Terada T, Noda S, Inui KI. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125–34.
11. Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7:1–36. Available from: https://www.nature.com/articles/s41392-022-01168-8
12. Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer 2021;7:1–12. Available from: https://www.nature.com/articles/s41523-021-00265-1
13. Kollipara S, Chougule M, Boddu R, Bhatia A, Ahmed T. Playing hide-and-seek with tyrosine kinase inhibitors: can we overcome administration challenges? AAPS J. 2024;26:1–19. doi: https://doi.org/10.1208/s12248-024-00939-1
14. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–57. Available from: https://www.nature.com/articles/1203957
15. Selick HE, Beresford AP, Tarbit MH. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov Today. 2002;7:109–16. doi: https://doi.org/10.1016/j.ejps.2021.105812
16. Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an UNGAP review. Eur J Pharm Sci. 2021;162:105812. doi: https://doi.org/10.3389/fonc.2023.1146108
17. Cheng F, Li Q, Cui Z, Hong M, Li W, Zhang Y. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: from clinical trials to real-life settings. Front Oncol. 2023;13:1146108.
18. Gerritse SL, Janssen JBE, Labots M, de Vries R, Rudek M, Carducci M, et al. High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: a systematic review. Cancer Treat Rev. 2021;97:102171.
19. Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010;16:4446–51. Available from: https://doi.org/10.1158/1078-0432.CCR-10-0663
20. Haddad FG, Nasnas C, Sasaki K, Paul S, Issa GC, Rausch C, et al. Using proton pump inhibitors is not associated with adverse outcomes in patients with chronic myeloid leukemia treated with dasatinib. Clin Lymphoma Myeloma Leuk. 2024;24:484–7. Available from: http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152265024000922/fulltext
21. van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, et al. Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options. Clin Pharmacokinet. 2017;56:683–8. doi: https://doi.org/10.1007/s40262-016-0503-3
22. Numico G, Fusco V, Franco P, Roila F. Proton pump inhibitors in cancer patients: how useful they are? A review of the most common indications for their use. Crit Rev Oncol Hematol. 2017;111:144–51.
23. Sharma M, Holmes HM, Mehta HB, Chen H, Aparasu RR, Shih YCT, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125:1155–62. doi: https://doi.org/10.1002/cncr.31917
24. Hofmann J, Bart?n?k A, Hauser T, Sedmak G, Beránek J, Ryšánek P, et al. Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans. Leukemia. 2023;37:2486–92. Available from: https://www.nature.com/articles/s41375-023-02045-1
25. Kollipara S, Ahmed T, Praveen S. Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors. Xenobiotica. 2023;53:366–81. doi: https://doi.org/10.1080/00498254.2023.2250856
26. Kollipara S, Ahmed T, Praveen S. Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers. Xenobiotica. 2023;53:339–56. doi: https://doi.org/10.1080/00498254.2023.2246153
27. Saeheng T, Na-Bangchang K, Karbwang J. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review. Eur J Clin Pharmacol. 2018;74:1365–76. doi: https://doi.org/10.1007/s00228-018-2513-6
28. Boddu R, Kollipara S, Kambam V, Khan SM, Behera S, Murty NNVVSSN, et al. Novel omeprazole delayed release orally disintegrating tablets for enhanced patient compliance: a case of model informed formulation development. Xenobiotica. 2024;54(9):629–41. doi: https://doi.org/10.1080/00498254.2024.2391519
29. Kollipara S, Martins FS, Sanghavi M, Santos GML, Saini A, Ahmed T. Role of physiologically based biopharmaceutics modeling (PBBM) in fed bioequivalence study waivers: regulatory outlook, case studies and future perspectives. J Pharm Sci. 2024;113:345–58. doi: https://doi.org/10.1016/j.xphs.2023.11.030
30. Bhattiprolu AK, Kollipara S, Boddu R, Arumugam A, Khan SM, Ahmed T. A semi-mechanistic physiologically based biopharmaceutics model to describe complex and saturable absorption of metformin: justification of dissolution specifications for extended release formulation. AAPS PharmSciTech. 2024;25:1–19. doi: https://doi.org/10.1208/s12249-024-02904-9
31. Kollipara S, Prabhat PK, Saha P, Gupta S, Naidu VR, Ahmed T. Physiologically based biopharmaceutics modeling coupled with biopredictive dissolution in development of bioequivalent formulation for mesalamine enteric coated tablet: a tough nut to crack. AAPS PharmSciTech. 2025;26:1–19. doi: https://doi.org/10.1208/s12249-024-02990-9
32. Reagents: buffer solutions [Internet]. [cited 2024 Dec 21]. Available from: http://www.uspbpep.com/usp29/v29240/usp29nf24s0_ris1s119.html
33. Kovar C, Loer HLH, Rüdesheim S, Fuhr LM, Marok FZ, Selzer D, et al. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2024;13:1144–59. Available from: https://pubmed.ncbi.nlm.nih.gov/38693610/
34. Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig. 2013;33:589–95. doi: https://doi.org/10.1007/s40261-013-0103-z
35. Yamazaki S, Loi CM, Kimoto E, Costales C, Varma M V. Application of physiologically based pharmacokinetic modeling in understanding bosutinib drug-drug interactions: importance of intestinal P-glycoprotein. Drug Metab Dispos. 2018;46:1200–11. Available from: https://pubmed.ncbi.nlm.nih.gov/29739809/
36. Abbas R, Chalon S, Leister C, Gaaloul M El, Sonnichsen D. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71:123–32. doi: https://doi.org/10.1007/s00280-012-1987-7
37. Hsyu PH, Pignataro DS, Matschke K. Absolute bioavailability of bosutinib in healthy subjects from an open-label, randomized, 2-period crossover study. Clin Pharmacol Drug Dev. 2018;7:373–81. doi: https://doi.org/10.1002/cpdd.396
38. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet. 2005;44:1165–77. doi: https://doi.org/10.2165/00003088-200544110-00004
39. Heimbach T, Musuamba Tshinanu F, Raines K, Borges L, Kijima S, Malamatari M, et al. PBBM considerations for base models, model validation, and application steps: workshop summary report. Mol Pharm. 2024;21:5353–72. doi: https://doi.org/10.1021/acs.molpharmaceut.4c00758
40. Boddu R, Kollipara S, Vijaywargi G, Ahmed T. Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions. Xenobiotica. 2023;53:260–78. doi: https://doi.org/10.1080/00498254.2023.2238048
41. Korashy HM, Rahman AFMM, Kassem MG. Dasatinib. Profiles Drug Subst Excip Relat Methodol. 2014;39:205–37.
42. Wu D, Sanghavi M, Kollipara S, Ahmed T, Saini AK, Heimbach T. Physiologically based pharmacokinetics modeling in biopharmaceutics: case studies for establishing the bioequivalence safe space for innovator and generic drugs. Pharm Res. 2023;40:337–57. doi: https://doi.org/10.1007/s11095-022-03319-6
43. Xia B, Heimbach T, He H, Lin TH. Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos. 2012;33:536–49. doi: https://doi.org/10.1002/bdd.1821
44. FDA. Highlights of prescribing information. [cited 2024 Dec 22]; Available from: www.fda.gov/medwatch
45. FDA, cder. label. [cited 2024 Dec 22]; Available from: www.fda.gov/medwatch
46. FDA, cder. Highlights of prescribing information. [cited 2024 Dec 22]; Available from: www.fda.gov/medwatch
47. Dodd S, Kollipara S, Sanchez-Felix M, Kim H, Meng Q, Beato S, et al. Prediction of ARA/PPI drug-drug interactions at the drug discovery and development interface. J Pharm Sci. 2019;108:87–101.
48. Lewis LD, Koch KM, Reddy NJ, Cohen RB, Lewis NL, Whitehead B, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009;27:1191–6. doi: https://doi.org/10.1200/JCO.2008.18.3285
49. Xu F, Lee K, Xia W, Liao H, Lu Q, Zhang J, et al. Administration of lapatinib with food increases its plasma concentration in chinese patients with metastatic breast cancer: a prospective phase II study. Oncologist. 2020;25:e1286–91. doi: https://doi.org/10.1634/theoncologist.2020-0044
50. Ferrer F, Tetu P, Dousset L, Lebbe C, Ciccolini J, Combarel D, et al. Tyrosine kinase inhibitors in cancers: treatment optimization – Part II. Crit Rev Oncol Hematol. 2024;200:104385.
51. FDA. Highlights of prescribing information full prescribing information: contents* 1 Indications and usage 2 dosage and administration 2.1 Antidiarrheal prophylaxis 2.2 Recommended dose and schedule 2.3 Dose modifications 3 Dosage forms and strengths 4 Contraindications 5 Warnings and precautions 5.1 Diarrhea 5.2 Hepatotoxicity 5.3 Embryo-fetal toxicity 6 Adverse reactions 6.1 Clinical trials experience 7 Drug interactions 7.1 Effect of other drugs on NERLYNX 7.2 Effect of NERLYNX on other. 2017 [cited 2024 Dec 22]; Available from: Available from: www.fda.gov/medwatch
52. FDA. ZELBORAF (vemurafenib) tablet for oral use. [cited 2024 Dec 22]; Available from: www.fda.gov/medwatch
53. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42:676–9. Available from: https://journals.lww.com/jcge/fulltext/2008/07000/addition_of_a_h2_receptor_antagonist_to_ppi.5.aspx
54. Hashimoto H, Kushikata T, Kudo M, Hirota K. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist? J Gastroenterol. 2007;42:275–8. doi: https://doi.org/10.1007/s00535-006-1946-3
55. Raoul JL, Guérin-Charbonnel C, Edeline J, Simmet V, Gilabert M, Frenel JS. Prevalence of proton pump inhibitor use among patients with cancer. JAMA Netw Open. 2021;4:e2113739. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781174
56. Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, et al. Proton pump inhibitors and oncologic treatment efficacy: a practical review of the literature for oncologists. Curr Oncol. 2021;28:783–99. Available from: https://www.mdpi.com/1718-7729/28/1/76/htm
57. Lee JE, Kwon SH, Kwon S, Jung HI, Nam JH, Lee EK. Concomitant use of proton pump inhibitors and palbociclib among patients with breast cancer. JAMA Netw Open. 2023;6:e2324852. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807485
58. Buti S, Tommasi C, Scartabellati G, De Giorgi U, Brighi N, Rebuzzi SE, et al. The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Anticancer Drugs. 2022;34:178. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9760470/
59. Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92:203–13. doi: https://doi.org/10.1038/clpt.2012.73
60. Larfors G, Andersson P, Jesson G, Liljebris C, Brisander M, Lennernäs H, et al. Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug–drug interactions. Eur J Haematol. 2023;111:644–54. doi: https://doi.org/10.1111/ejh.14059
61. Mitra A, Parrott N, Miller N, Lloyd R, Tistaert C, Heimbach T, et al. Prediction of pH-dependent drug-drug interactions for basic drugs using physiologically based biopharmaceutics modeling: industry case studies. J Pharm Sci. 2020;109:1380–94.
62. Parrott N, Stillhart C, Lindenberg M, Wagner B, Kowalski K, Guerini E, et al. Physiologically based absorption modelling to explore the impact of food and gastric pH changes on the pharmacokinetics of entrectinib. AAPS J. 2020;22:1–13. doi: https://doi.org/10.1208/s12248-020-00463-y
63. Heimbach T, Kesisoglou F, Novakovic J, Tistaert C, Mueller- Zsigmondy M, Kollipara S, et al. Establishing the bioequivalence safe space for immediate-release oral dosage forms using physiologically based biopharmaceutics modeling (PBBM): case studies. J Pharm Sci. 2021;110:3896–906. Available from: http://jpharmsci.org/article/S002235492100486X/fulltext
64. Segregur D, Flanagan T, Mann J, Moir A, Karlsson EM, Hoch M, et al. Impact of acid-reducing agents on gastrointestinal physiology and design of biorelevant dissolution tests to reflect these changes. J Pharm Sci. 2019;108:3461–77. Available from: http://jpharmsci.org/article/S0022354919304241/fulltext
65. Segregur D, Mann J, Moir A, Karlsson EM, Dressman J. Biorelevant in vitro tools and in silico modeling to assess pH-dependent drug-drug interactions for salts of weak acids: case example potassium raltegravir. J Pharm Sci. 2022;111:517–28. Available from: http://jpharmsci.org/article/S0022354921004858/fulltext
66. Segregur D, Barker R, Mann J, Moir A, Karlsson EM, Turner DB, et al. Evaluating the impact of acid-reducing agents on drug absorption using biorelevant in vitro tools and PBPK modeling - case example dipyridamole. Eur J Pharm Sci. 2021;160:105750. doi: https://doi.org/10.1016/j.ejps.2021.105750
67. Kuminek G, Salehi N, Waltz NM, Sperry DC, Greenwood DE, Hate SS, et al. Use of gastrointestinal simulator, mass transport analysis, and absorption simulation to investigate the impact of pH modifiers in mitigating weakly basic drugs’ performance issues related to gastric pH: palbociclib case study. Mol Pharm. 2023;20:147–58. doi: https://doi.org/10.1021/acs.molpharmaceut.2c00545
Year
Month